CBD Reduced Lung Inflammation in Mice Through Adenosine Receptor Activation
A single dose of CBD significantly reduced multiple markers of lung inflammation in a mouse model of acute lung injury, and the effect worked through adenosine A2A receptor signaling.
Quick Facts
What This Study Found
Researchers induced acute lung injury in mice using LPS (a bacterial toxin) and administered a single 20 mg/kg dose of CBD beforehand. CBD decreased neutrophil migration into the lungs, reduced protein leakage (indicating less tissue damage), lowered the enzyme myeloperoxidase (a marker of neutrophil activity), and reduced pro-inflammatory cytokines (TNF and IL-6) and chemokines (MCP-1 and MIP-2).
These anti-inflammatory effects persisted at 1, 2, and 4 days after injury. Critically, when researchers blocked the adenosine A2A receptor with a selective antagonist, all of CBD's anti-inflammatory effects were abolished, confirming this receptor as the mechanism.
Key Numbers
Single dose of 20 mg/kg CBD. Anti-inflammatory effects measured at days 1, 2, and 4 post-injury. CBD reduced neutrophils, albumin, myeloperoxidase, TNF, IL-6, MCP-1, and MIP-2. All effects abolished by adenosine A2A receptor antagonist.
How They Did This
Mouse model of acute lung injury induced by LPS. CBD (20 mg/kg) was administered before injury. Outcomes measured included leukocyte migration, albumin concentration in bronchoalveolar lavage fluid, myeloperoxidase activity, and cytokine/chemokine levels. The adenosine A2A receptor antagonist ZM241385 was used to test the mechanism.
Why This Research Matters
Acute lung injury is a serious inflammatory condition with no established pharmacological treatment beyond supportive care. This study identified CBD as a potent anti-inflammatory agent in this context and pinpointed the specific receptor mechanism, which could guide development of targeted treatments.
The Bigger Picture
This study contributes to understanding CBD's anti-inflammatory mechanisms beyond the endocannabinoid system. The adenosine A2A receptor pathway is a well-established anti-inflammatory signaling system, and CBD's ability to engage it opens possibilities for treating inflammatory lung conditions.
What This Study Doesn't Tell Us
This was a mouse study, and the LPS model of acute lung injury does not perfectly replicate the human condition. CBD was given before injury (pre-treatment), which differs from the clinical scenario where treatment begins after injury occurs. Dosing may not translate directly to human applications.
Questions This Raises
- ?Would CBD be effective when administered after acute lung injury has already begun?
- ?What doses would be needed in humans?
- ?Could CBD benefit other inflammatory lung conditions through the same adenosine pathway?
- ?Would combining CBD with other adenosine-enhancing drugs improve outcomes?
Trust & Context
- Key Stat:
- All anti-inflammatory effects of CBD were abolished when the A2A receptor was blocked
- Evidence Grade:
- Animal study with a clear mechanism identified; preliminary evidence that needs human validation.
- Study Age:
- Published in 2012. CBD anti-inflammatory research has expanded significantly since, including interest during the COVID-19 pandemic.
- Original Title:
- Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: role for the adenosine A(2A) receptor.
- Published In:
- European journal of pharmacology, 678(1-3), 78-85 (2012)
- Authors:
- Ribeiro, Alison, Ferraz-de-Paula, Viviane, Pinheiro, Milena L, Vitoretti, Luana B, Mariano-Souza, Domenica P, Quinteiro-Filho, Wanderley M, Akamine, Adriana T, Almeida, Vinícius I, Quevedo, João, Dal-Pizzol, Felipe, Hallak, Jaime E, Zuardi, Antônio W, Crippa, José A, Palermo-Neto, João
- Database ID:
- RTHC-00609
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
How does CBD reduce inflammation in the lungs?
In this study, CBD increased adenosine signaling through the A2A receptor, a well-known anti-inflammatory pathway. This reduced the migration of immune cells (neutrophils) into the lungs, decreased tissue damage markers, and lowered levels of multiple inflammatory molecules.
Could CBD treat lung injuries in humans?
This study used a mouse model, so the results cannot be directly applied to humans. However, the clear mechanism through the adenosine A2A receptor provides a solid biological basis for further investigation. Human clinical trials would be needed to determine efficacy and appropriate dosing.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- how-to-tell-if-weed-is-moldy
Cite This Study
https://rethinkthc.com/research/RTHC-00609APA
Ribeiro, Alison; Ferraz-de-Paula, Viviane; Pinheiro, Milena L; Vitoretti, Luana B; Mariano-Souza, Domenica P; Quinteiro-Filho, Wanderley M; Akamine, Adriana T; Almeida, Vinícius I; Quevedo, João; Dal-Pizzol, Felipe; Hallak, Jaime E; Zuardi, Antônio W; Crippa, José A; Palermo-Neto, João. (2012). Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: role for the adenosine A(2A) receptor.. European journal of pharmacology, 678(1-3), 78-85. https://doi.org/10.1016/j.ejphar.2011.12.043
MLA
Ribeiro, Alison, et al. "Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: role for the adenosine A(2A) receptor.." European journal of pharmacology, 2012. https://doi.org/10.1016/j.ejphar.2011.12.043
RethinkTHC
RethinkTHC Research Database. "Cannabidiol, a non-psychotropic plant-derived cannabinoid, d..." RTHC-00609. Retrieved from https://rethinkthc.com/research/ribeiro-2012-cannabidiol-a-nonpsychotropic-plantderived
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.